Sarcoma of the female reproductive system
Conditions
Interventions
Genital sarcoma group:None
Uterine leiomyoma patients group:None
Sponsors
The First Affiliated Hospital of University of Science and Technology of China
Eligibility
Sex/Gender
Female
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Inclusion criteria for women with sarcoma of the reproductive system: (1) Patients with persistent/recurrent (including unstaged) sarcoma of the female reproductive system confirmed by pathology. Patients who are not staged (those who have not had hysterectomy or ovarian surgery) are also eligible and should be listed as ''not staged'' if the only histological (pathological) record of the disease is biopsy or curettage. If these patients have a record of metastatic disease, they should be assigned to the appropriate stage (III/IV). (2) The disease should be confirmed by a pathologist to meet one of the following conditions: 1) Uterus (tumor ICD-O code) : Leiomyosarcoma of uterus (8890/3); Epithelial leiomyosarcoma (8891/3); Myxoid leiomyosarcoma (8896/3); Low-grade endometrial stromal sarcoma (8931/3); Low-grade endometrial stromal sarcoma (8930/3); Undifferentiated sarcoma (8805/3); Rhabdomyosarcoma (8900/3); Carcinosarcoma (8980/3); Adenosarcoma (8933/3). 2) Ovarian (tumor ICD-O coding) : High-grade endometrioid stromal sarcoma (8930/3); Low-grade endometrioid stromal sarcoma (8931/3); Adenosarcoma (8933/3); Carcinosarcoma (8980/3); Fibrosarcoma (8810/3); Leiomyosarcoma (8890/3). 3) Fallopian tube (tumor ICD-O code) : Malignant Miller mixed tumor/carcinosarcoma (8950/3); Adenosarcoma (8933/3); Leiomyosarcoma (8890/3). 4) Broad ligament or other uterine ligament (tumor ICD-O code) : Adenosarcoma (8933/3); Leiomyosarcoma (8890/3). 5) Lower genital tract (tumor ICD-O code) : Liposarcoma (8850/3); Highly differentiated liposarcoma (8851/3); Dedifferentiated liposarcoma (8858/3); Pleomorphic liposarcoma (8854/3); Myxoid liposarcoma (8852/3); Leiomyosarcoma (8890/3); Epithelioid leiomyosarcoma (8891/3); Myxoid leiomyosarcoma (8896/3); Carcinosarcoma (8980/3); Adenosarcoma (8933/3). 6) Other rare sarcomas of the female reproductive system (tumor ICD-O code) : Embryonal rhabdomyosarcoma (8910/3); Alveolar rhabdomyosarcoma (8920/3); Pleomorphic rhabdomyosarcoma (8901/3); Vesicular soft tissue sarcoma (9581/3); Ewing's sarcoma (8364/3); Fibrosarcoma protuberans of the skin (8832/3); Fibrosarcoma protuberans of the skin (8832/1); Fibrosarcoma protuberans pigmentosa (8833/1); Kaposi's sarcoma (9140/3); Angiosarcoma (9120/3). 3) The first enrolled patient must be diagnosed after January 1, 2018, and the last enrolled patient must be diagnosed before December 31, 2028. (4) Complete clinical data and complete follow-up work. (5) Apply for a waiver of informed consent or voluntarily sign an informed consent approved by the Research Ethics Committee (EC) prior to enrollment in the study. 2. Inclusion criteria for patients with uterine leiomyoma: (1) Radiological or histopathological evaluation of newly diagnosed persistent/recurrent leiomyoma of the uterus ruled out the possibility of malignancy. (2) The first enrolled patient must be diagnosed after January 1, 2018, and the last enrolled patient must be diagnosed before December 31, 2028.
Exclusion criteria
Exclusion criteria: 1. Patients who have participated in other biomedical studies or received experimental treatments in the past 30 days, unless approved by the investigator; 2. Patients lost follow-up without reason during the study; 3. There is a severe or uncontrolled bacterial, fungal, or viral infection that, in the opinion of the principal investigator, may interfere with the patient's participation in the study or the evaluation of the results; 4. Any disease or medical condition that is unstable or may jeopardize patient safety and compliance with this study; 5. Previous history of malignant tumors or concurrent other malignant tumors or multiple primary tumors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lactate dehydrogenase;Carbohydrate antigen 125;Imaging manifestation;Pathological behavior;Overall survival;Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pathological behavior;Age of onset; | — |
Countries
China
Contacts
Public ContactZhou Ying
The First Affiliated Hospital of University of Science and Technology of China
Outcome results
None listed